Over the past two months, I added three new stocks to my portfolio.
All very different businesses. One’s making the tech behind electric vehicles. One’s building the chips powering AI. And one’s trying to rewire the way we discover medicines.
But the common thread? They’re future-focused. Backed by real fundamentals. And not just “hot” names on social media.
Here’s a breakdown of each — the story and the numbers.
1. Sona BLW – India’s EV Backbone
Sona BLW isn’t loud on Twitter. But it’s quietly becoming a major player in the EV supply chain — they make precision gears, motors, and drivetrains used in EVs and hybrids.
This isn’t a “future potential” kind of bet. They’re already supplying global automakers, and with the EV shift picking up in India and abroad, the tailwinds are strong.
Here’s what sealed it for me:
- Revenue: 3 year CAGR growth – 26.69%
- Operating Profit Margin: Solid 28.1%
- Net Profit: ₹518 Cr in FY24, up from ₹395 Cr last year
- Debt-to-Equity: 0.09 — nearly debt-free
- EPS: ₹9.57 and improving year-on-year
- My average buying price: ₹481.38
In short: stable business, clean balance sheet, future-ready product line. Also, I’m betting on India getting benefitted from the manufacturing shift from China due to heavy US tariff and uncertainty.
2. AMD – Chips are the New Oil
I’ve had my eye on semiconductors for a while. When I finally pulled the trigger, I went with AMD.
Why? Because they’re not just playing catch-up to Nvidia — they’re going after specific markets and winning. Data centers, gaming, high-performance computing, and now AI workloads.
What gave me conviction:
- Revenue: $25.8 billion in FY24 — up 14%
- Net Income: $1.6 billion — 92% jump
- Data Center Segment: Grew 57% YoY to $3.7 billion in Q1 FY25
- AI bet: Strong product pipeline + double-digit growth expected in this segment
- My average buying price: $98.70
Sure, Nvidia’s the poster child of AI. But it’s already had a run. Where do partner companies will look for when they need an option?
AMD is the quieter compounding machine. Cheaper valuation, strong fundamentals, and deep R&D bets.
3. Recursion Pharma – My Moonshot
Every portfolio needs that one risky, asymmetric bet. For me, that’s Recursion.
They’re combining biotech with machine learning to speed up drug discovery. It’s risky. It’s bleeding-edge. And it won’t pay off tomorrow. Nvidia has invested in this company and that’s what brought this company to my attention.
Here’s what I looked at:
- Revenue: $58.8M in FY24, up from $44.6M
- Net Loss: $463M — yeah, they’re burning cash
- Collaborations: Received $30M from Roche & Genentech
- Backers: Nvidia, Bayer, and others have skin in the game
- My average buying price: $5.32
This isn’t a traditional pick. I’m not chasing near-term profits. I’m betting that AI won’t just build apps — it’ll build cures. And Recursion could be part of that shift.
I bought these US stocks using INDMoney app.
The transfer of funds to US Wallet was faster and convenient. App UI is simple and has everything you need.
If you are investing in US market, be prepared to hold long term to get taxed less as long term capital gain tax is lesser than short term capital gains. Also, invest in bigger chunks to reduce the remittance charges.
Vinay Mundhe 